Florida Cancer Specialists & Research Institute supports the colonoscopy guidelines of the American Cancer Society

Colorectal cancer screening tests are effective in saving lives; European colonoscopy study is misleading

Foot. Myers, Fla., Nov. 22, 2022 (GLOBE NEWSWIRE) — Cancer Research Institute and Specialists of Florida, LLC (FCS) opposes a recent study published in the New England Journal of Medicine suggesting that colonoscopies are not as effective in preventing colorectal cancer deaths as previously thought.

“The authors’ inference that colonoscopies may not be beneficial is misleading,” said FCS President and Managing Physician Michael Diaz, MD. “Based on numerous recent studies and the experience of our own FCS medical experts who have provided cancer care to hundreds of thousands of patients over the past 37 years, the data clearly shows that colonoscopies are among the best tools available. to detect and prevent colon cancer.

The clinical trial involving more than 80,000 adults in Poland, Norway and Sweden was conducted by physicians at the University of Oslo and Oslo University Hospital between 2009 and 2014 to assess the risks of colorectal cancer and related death compared with death from any cause.

Dr. Karen Knudsen, Executive Director of the American Cancer Society, shared in response to the study: “Preventive cancer screening is the best and most reliable way to save lives. That’s why the American Cancer Society recommends colorectal cancer screening, including colonoscopy, for adults age 45 and older. There is no reason to change that address. Recommended cancer screening tests should be a routine part of good health.”

FCS Director of Drug Development Manish Patel, MD adds, “Only 42% of people in the ‘invited screening group’ underwent colonoscopies, obscuring interpretation of the results.” He also notes that the study was limited to participants living in Norway, Poland and Sweden.

There are often no signs or symptoms of polyps or colorectal cancer, which is why screening is so important. A recent study co-authored by FCS, conducted for the Community Oncology Alliance (COA) by Avalere Health and published in the November 2020 issue of JCO Clinical Cancer Informatics, supports these facts. “Due to fear of exposure to COVID-19 during the height of the pandemic, many Americans delayed or even skipped regular screening tests,” said FCS Medical Director of Therapeutics and Analysis Lucio N. Gordan, MD. “This resulted in a number of cancers, including colorectal cancers, being diagnosed at later stages when treatment is more complex and mortality rates are higher.”

“Increasingly, thanks to ongoing clinical advances in screening technology and the range of precision personalized cancer treatments offered by our statewide practice, a growing number of patients diagnosed with colon cancer are living longer and enjoying life to the fullest. said Dr. Diaz.

FCS Executive Director Nathan H. Walcker advocates for regular screening: “FCS supports the American Cancer Society (ACS) guidelines that adults at average risk should begin screening for breast cancer. colon at age 45 and continue until at least age 75. Walcker adds: “We know very well that cancer does not discriminate based on age, race, geography or economic position. For this reason, it is equally important that everyone have adequate access to cancer screening tests, regardless of their circumstances. FCS aligns with the ACS in encouraging everyone to participate in regular assessments.”

The American Cancer Society offers a website, Cancer.org/get-screened, which provides resources for screening guidelines for various types of cancer and guidance on finding free and low-cost screening tests to ensure everyone has access. to appropriate preventive care.

Colon Cancer Facts:

Overall, in the US, 1 in 23 men (4.4%) and 1 in 25 women (4.1%) are at risk of developing colon or colorectal cancer in their lifetime. It is the third most common form of cancer and the second leading cause of cancer death in the nation. The risk increases with age. Most cases occur in adults older than 50 years.

For colon cancer, the median age at diagnosis is 66 for men and 69 for women. Although it is recommended that screening be done between the ages of 45 and 75, keep in mind that for people ages 76 to 85, the decision to get tested should be based on individual preferences, life expectancy, general health, and previous screening history. People over the age of 85 should no longer be screened for colorectal cancer.

Colorectal cancer encompasses cancer of the colon and rectum, which are parts of the digestive system that process and help remove food, water, and waste from the body. This form of cancer occurs when cells grow out of control and form polyps that, over time, can become cancerous.

Screening tests can detect polyps at an early stage, so they can be removed before they turn into cancer. When detected in its early stages, colon cancer is more likely to be cured; the treatment is less extensive and the recovery is much faster. The five-year survival rate when colon cancer is diagnosed in its early stages (stage 1 and stage 2) is 90 percent.


About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)

Recognized by the American Society of Clinical Oncology (ASCO) with a National Clinical Trial Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. Most of the new cancer drugs recently approved for use in the US have been studied in clinical trials with the participation of Florida Cancer Specialists.* Trained at prestigious medical schools and research institutes, our doctors are consistently ranked Nationally as Top Doctors by US News & World Report.

Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence reflected in exceptional and compassionate patient care, fueled by innovative clinical research, cutting-edge technologies, and advanced treatments, including targeted therapies, genomics-based treatments and immunotherapy. Our highest values ​​are embodied in our outstanding team of highly trained and dedicated physicians, clinicians and staff.

*Prior to approval

Attached file

Michelle Robey, Vice President, Marketing Florida Cancer Specialists & Research Institute (813) 767-9398 [email protected] Jen Bradley, Director, Corporate Communications Florida Cancer Specialists & Research Institute (847) 280-1740 [email protected] 

Leave a Reply

Your email address will not be published. Required fields are marked *